|Company Name||Novavax, Inc.|
On December 18, 2017, Novavax announced that “a complete Phase 1/2 data package” associated with its NanoFlue vaccine would not be expected until February of 2018, in part because “the wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability.”
On this news, shares of Novavax fell $0.40, or 26.8%, to close at $1.09 on December 19, 2017, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Novavax, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.